Trastuzumab Withdrawn Phase 2 Trials for Cancer, Breast Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00057993Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
NCT00054470Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
NCT00964704A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
NCT00434031CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer